PhoenixBio Co., Ltd. (6190) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for PhoenixBio Co., Ltd. (6190:JPX), powered by AI.

Current Price
¥380
P/E Ratio
-3.4
Market Cap
1.5B
Sector
Healthcare
What is the PhoenixBio Co., Ltd. stock price forecast?

PhoenixBio Co., Ltd. is currently trading at ¥380. View real-time AI analysis on Alpha Lenz.

What is PhoenixBio Co., Ltd. insider trading activity?

View the latest insider trading data for PhoenixBio Co., Ltd. on Alpha Lenz.

What is PhoenixBio Co., Ltd.'s P/E ratio?

PhoenixBio Co., Ltd.'s P/E ratio is -3.4.

PhoenixBio Co., Ltd.

JPX · 6190
¥380-1(-0.26%)Market closedJPX regular session 09:00–15:00 JST
Ask about PhoenixBio Co., Ltd.'s future dividend policy...
Alpha Chat Insight

PhoenixBio Co., Ltd. trades at a P/E of -3.4 (undervalued) with modest ROE of -28.4%.

Ask for details

Company Overview

PhoenixBio Co., Ltd. is a biotechnology company dedicated to the development of cutting-edge bio-research products. The primary focus of PhoenixBio is on creating and distributing high-quality human liver-based research tools and technology platforms. These products are essential for pharmaceutical companies and research institutions engaged in drug discovery and development, particularly in areas like toxicology and pharmacology where precise human liver models can significantly impact research outcomes. With a commitment to innovation, PhoenixBio primarily serves the scientific and medical research communities, facilitating advancements in understanding liver diseases and their treatments. Located in Japan, PhoenixBio has carved out a significant niche by offering proprietary bioengineered models that simulate human liver functions, thus enhancing the drug discovery process. Its role in the market is crucial, acting as a bridge between pure scientific research and practical applications in medicine, particularly in developing safer and more efficient pharmaceuticals.

CEOTakashi Shimada
SectorHealthcare
IndustryBiotechnology
Employees69

Company Statistics

FY 2025

Profile

¥1,536,964,720Market Cap
¥1,541,388,000Revenue
0.00Shares Out
69Employees

Margins

72.51%Gross
-5.90%EBITDA
-9.22%Operating
-28.08%Pre-Tax
-29.13%Net

Valuation

-3.42P/E
1.13P/B
1.00EV/Sales
-10.48EV/EBITDA
-14.59P/FCF

Growth (CAGR)

5.18%Rev 3Yr
3.29%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-17.95%ROA
-28.39%ROE
-17.10%ROIC

Financial Health

¥1,149,390,000Cash & Cash Equivalents
¥-229,454,000Net Debt
67.37%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

PhoenixBio Co., Ltd. (ticker: 6190) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 69 employees. Market cap is $1.5B.

The current price is 380 with a P/E ratio of -3.42x and P/B of 1.13x.

ROE is -28.39% and operating margin is -9.22%. Annual revenue is $1.5B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
PhoenixBio Co., Ltd. (6190) Stock Forecast 2026 ¥380 — Price, Financials & Analyst Targets | Alpha Lenz